Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Humans
Nivolumab
/ administration & dosage
Paclitaxel
/ administration & dosage
Practice Guidelines as Topic
Prognosis
Stomach Neoplasms
/ drug therapy
Treatment Outcome
Ramucirumab
Gastric cancer
Prognostic factor
RECIST
Tumor marker
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
12
12
2019
accepted:
16
04
2020
pubmed:
30
4
2020
medline:
2
9
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
After failure of first-line chemotherapy with fluoropyrimidines and platinum compounds for advanced gastric cancer, second-line chemotherapy with ramucirumab plus paclitaxel, which elicits a durable response, and third-line or later chemotherapy with nivolumab have been shown to lead to a more favorable prognosis in advanced gastric cancer patients. As new and more effective drugs are now available, sequential chemotherapy would contribute to prolonged survival. From this point of view, the patient's disease course should be frequently monitored in order to adapt treatment regimens. This review summarizes the points to note in regard to radiological assessment, and discusses the integration of prognostic factors, tumor markers, and clinical symptoms that need to be taken into account to change treatment at an appropriate timing.
Identifiants
pubmed: 32347434
doi: 10.1007/s10147-020-01684-z
pii: 10.1007/s10147-020-01684-z
pmc: PMC7329754
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers, Tumor
0
Nivolumab
31YO63LBSN
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1223-1232Commentaires et corrections
Type : ErratumIn
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastric Cancer. 2012 Apr;15(2):154-61
pubmed: 21892754
Acta Oncol. 2009;48(3):385-90
pubmed: 18855156
Cancer Chemother Pharmacol. 2018 Jun;81(6):981-989
pubmed: 29600386
Ann Surg Oncol. 2008 Aug;15(8):2336-44
pubmed: 18521687
Br J Cancer. 2017 Jun 6;116(12):1526-1535
pubmed: 28463962
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
J Gastric Cancer. 2017 Jun;17(2):132-144
pubmed: 28680718
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2013 Dec 10;31(35):4438-44
pubmed: 24190112
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
Am J Gastroenterol. 1996 Jan;91(1):49-53
pubmed: 8561143
Int J Clin Oncol. 2014 Aug;19(4):656-61
pubmed: 23999902
Anticancer Res. 2014 Sep;34(9):5169-74
pubmed: 25202110
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ann Oncol. 2010 Sep;21(9):1779-1785
pubmed: 20150573
Br J Cancer. 2008 Nov 4;99(9):1402-7
pubmed: 18971936
Pathobiology. 2014;81(2):78-85
pubmed: 24401755
Eur J Cancer. 1992;28A(8-9):1351-4
pubmed: 1515249
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Ann Oncol. 2016 Apr;27(4):687-92
pubmed: 26787231
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28
pubmed: 24366758
Curr Med Res Opin. 2019 Feb;35(2):275-282
pubmed: 29785861
Cancer Chemother Pharmacol. 2011 Oct;68(4):913-21
pubmed: 21290247
Ann Oncol. 2016 Apr;27(4):673-9
pubmed: 26747859
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
Gastric Cancer. 2016 Jul;19(3):927-38
pubmed: 26510663
J Gastrointest Oncol. 2018 Feb;9(1):52-63
pubmed: 29564171
Br J Cancer. 2014 Mar 4;110(5):1163-8
pubmed: 24473399
Cancer Res. 1990 Jul 1;50(13):3952-5
pubmed: 2191769
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287
pubmed: 28404157
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
Cancer Chemother Pharmacol. 2008 Feb;61(2):301-7
pubmed: 17429626
Gastric Cancer. 2017 Sep;20(5):825-833
pubmed: 28028664
J Am Coll Surg. 1998 Jul;187(1):64-8
pubmed: 9660027
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
J Clin Oncol. 2004 Jun 15;22(12):2395-403
pubmed: 15197201
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
Gastric Cancer. 2019 Jul;22(4):684-691
pubmed: 30417313
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510
pubmed: 31101534
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Mol Clin Oncol. 2015 May;3(3):539-542
pubmed: 26137263
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259
Korean J Radiol. 2006 Oct-Dec;7(4):249-56
pubmed: 17143028
Acta Oncol. 2015 Jul;54(7):961-70
pubmed: 25984930
Gastric Cancer. 2003;6(3):142-5
pubmed: 14520526
Oncol Lett. 2016 May;11(5):2959-2964
pubmed: 27123046
Eur J Surg Oncol. 2001 Dec;27(8):731-9
pubmed: 11735169
Gastric Cancer. 2014;17(3):522-8
pubmed: 24162387
Ann Oncol. 2007 May;18(5):886-91
pubmed: 17298958
Gastric Cancer. 2014 Jan;17(1):26-33
pubmed: 23572188
Oncologist. 2014 Apr;19(4):358-66
pubmed: 24668328
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805